

Otlertuzumab

Cat. No.:	HY-P99212
CAS No.:	1372645-37-8
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Otlertuzumab (TRU-016) is a humanized anti-CD37 monoclonal antibody that can be used for cancer research ^[1] .
IC₅₀ & Target	CD37 ^[1]
In Vitro	Otlertuzumab (TRU-016) in combination with Rituximab (HY-P9913), Rapamycin (HY-10219), or Bendamustine (HY-13567) increases cell killing of NHL cells ^[2] . Otlertuzumab has the ability to bind to and kill CD37 ⁺ cells ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Otlertuzumab (TRU-016) in combination with Bendamustine (HY-13567) displays greater anti-tumor activity than either agent alone against a follicular lymphoma tumor model in SCID mice ^[2] . Otlertuzumab shows significant antitumor activity in mice bearing Ramos or Daudi tumor xenografts ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Byrd JC, et al. A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. *Blood*. 2014 Feb 27;123(9):1302-8.
- [2]. Baum P R, et al. Evaluation of the effect of TRU-016, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkin's lymphoma. *Journal of Clinical Oncology*, 2009, 27(15_suppl): 8571-8571.
- [3]. Cervený C G, et al. In vitro and in vivo anti-B cell lymphoma activities of TRU-016. *Journal of Clinical Oncology*, 2008, 26(15_suppl): 3074-3074.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA